Skip to main content
HOUSE 3932117th CongressReferred to the Subcommittee on Health.

PASTEUR Act of 2021

Last Action
8/2/2021

Actions

  • 2021-08-02Referred to the Subcommittee on Health.
  • 2021-06-17Referred to the Subcommittee on Health.
  • 2021-06-17Referred to the Subcommittee on Oversight, Management, and Accountability.
  • 2021-06-16Referred to the Subcommittee on Health.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, the Judiciary, and Homeland Security, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-06-16Introduced in House
  • 2021-06-16Introduced in House

CRS Summary

As of 2021-06-16 (00)

The Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2021 or the PASTEUR Act of 2021

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $11 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

Cosponsors (20)

  • A. Ferguson (R-GA)
  • Jake Auchincloss (D-MA)
  • Tony Cárdenas (D-CA)
  • Brian Fitzpatrick (R-PA)
  • Brad Wenstrup (R-OH)
  • Kim Schrier (D-WA)
  • Earl Carter (R-GA)
  • Chris Stewart (R-UT)
  • Maria Salazar (R-FL)
  • Michael Burgess (R-TX)
  • Sean Casten (D-IL)
  • Deborah Ross (D-NC)
  • DIANA DEGETTE (D-CO)
  • FRED UPTON (R-MI)
  • Marie Newman (D-IL)
  • G. K. Butterfield (D-NC)
  • Adrian Smith (R-NE)
  • Billy Long (R-MO)
  • Mark DeSaulnier (D-CA)
  • Don Bacon (R-NE)

Subjects

  • Administrative law and regulatory procedures
  • Advisory bodies
  • Appropriations
  • Congressional oversight
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Drug therapy
  • Executive agency funding and structure
  • Government information and archives
  • Government studies and investigations
  • Health programs administration and funding
  • Indian social and development programs
  • Infectious and parasitic diseases
  • Manufacturing
  • Medicaid
  • Medicare
  • Military medicine
  • Minority health
  • Prescription drugs
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.